KBY Biotech Indexv0.0.34
Search
← Pipeline|SNY-8628

SNY-8628

NDA/BLA
By Sanofi
Source: Trial-derived·Trials: 1
Modality
Radioligand
MOA
TYK2i
Target
B7-H3
Pathway
Neuroinflam
Pompe
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
~Apr 2019
→ ~Jul 2020
Phase 3
~Oct 2020
→ ~Jan 2022
NDA/BLA
Apr 2022
NDA/BLACurrent
NCT04357174
81 pts·Pompe
2022-04→TBD·Active
81 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
Q2
NDA/BLA
Active
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04357174NDA/BLAPompeActive81NT-proBNP
Competitors (10)
DrugCompanyPhaseTargetMOA
NidasacituzumabEli LillyApprovedCFTRTYK2i
LLY-4358Eli LillyPhase 3B7-H3CFTRmod
LisonaritideEli LillyPhase 3IL-13TYK2i
CeviglumideRocheNDA/BLAB7-H3CD47i
MRK-2473Merck & CoPhase 1/2Nectin-4TYK2i
ZorisotorasibAstraZenecaPhase 1WRNTYK2i
SNY-9600SanofiNDA/BLAB7-H3PD-L1i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
NVO-7840Novo NordiskPhase 2/3B7-H3GLP-1ag
NVO-7872Novo NordiskNDA/BLAB7-H3BTKi